Progress in the adjuvant treatment of colon cancer: Has it influenced clinical practice?

JAMA

Volumn 294, Issue 21, 2005, Pages 2758-2763

  Van Cutsem, Eric ^a   Costa, Frederico ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; COLON CANCER; COLON SURGERY; COLORECTAL CANCER; COMORBIDITY; EDITORIAL; HUMAN; LYMPH NODE; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SOCIAL STATUS; SURVIVAL RATE;

EID: 28844449340     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.21.2758     Document Type: Editorial

References (24)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481-488.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
4. American Joint Committee on Cancer. Missions and objectives. Available at: http://www.cancerstaging.org.
5. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
6. O'Connell J, Maggard M, Ko C. Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-1425.
7. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg. 2002;236:416-421.
8. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358.
9. Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes'B2 colon cancer. J Clin Oncol. 1995;13:2936-2943.
10. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: 5-year final report of INT-0089. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; 1998. Abstract 982.
11. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294:2703-2711.
12. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
13. Laurie JA, Moertel CG, Fleming TR, et al; The North Central Cancer Treatment Group and the Mayo Clinic. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol. 1989;7:1447-1456.
14. Brawley OW, Freeman HP. Race and outcomes: is this the end of the beginning for minority health research? J Natl Cancer Inst. 1999;91:1908-1909.
15. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49:664-666.
16. Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst. 2003;95:1545-1548.
17. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005;97:1211-1220.
18. Twelves C, Wong A, Nowacki M, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.
19. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, Fluorouracil and Leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
20. Wolmark N, Wieand SH, Kuebler J, Colangelo L, Smith R. A phase III trial comparing FULV + oxaliplatin in stage II or II carcinoma of the colon: results of NSAPB protocol C-07: late-breaking abstract 3500. In: Program and abstracts of the Annual Meeting of the American Society of Clinical Oncology; 2005. Available at: http://www.asco.org/ac/1,1003,_12-002643-00_18-0034-00_19-0031955, 00.asp. Accessed November 10, 2005.
21. Sargent D. Endpoints for colon adjuvant clinical trials: recommendations based on individual data from 20898 patients and 18 randomized trials [abstract]. J Clin Oncol. 2005;83:23.
22. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23:6639-6646.
23. Gwyn K, Bondy ML, Cohen DS, et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer. 2004;100:1595-1604.
24. Westra JL, Schaapveld M, Hollema H, et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol. 2005;23:5635-5643.